Deals

Everest Medicines Signs Strategic Cooperation Agreement with Hi-Sen Pharmaceutical to Supply and Commercialize Six Products in China
Everest MedicinesHi‑Sen Pharmaceutical

Everest Medicines Signs Strategic Cooperation Agreement with Hi-Sen Pharmaceutical to Supply and Commercialize Six Products in China

Everest Medicines (HKG: 1952) announced that it has entered into a strategic cooperation framework agreement with Hi‑Sen Pharmaceutical, establishing a framework for the supply, distribution, and related manufacturing and commercialization…

Betta Pharmaceuticals Acquires Global Rights to SS202 Ultra‑Long‑Acting Monthly Growth Hormone from Gensciences – Deal Valued at Up to RMB 50 Million Plus Royalties

Betta Pharmaceuticals Acquires Global Rights to SS202 Ultra‑Long‑Acting Monthly Growth Hormone from Gensciences – Deal Valued at Up to RMB 50 Million Plus Royalties

Astellas Inks Exclusive Option and License Deal for Audax's DAX-044 – Up to USD 1.3 Billion to Back Tumor-Targeted IL-12 Immunotherapy

Astellas Inks Exclusive Option and License Deal for Audax’s DAX-044 – Up to USD 1.3 Billion to Back Tumor-Targeted IL-12 Immunotherapy

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011
CancerImmvira Bioscience

Immvira Bio Files for Hong Kong IPO with Phase II Oncolytic Immunotherapy MVR-T3011

Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline
Exegenesis BioIPO

Exegenesis Bio Files for Hong Kong IPO with AI-Powered Gene Therapy Pipeline

QYuns' QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific
Auto-immuneCaldera Therapeutics

QYuns’ QX030N Partner Caldera Raises $112.5 Million for IBD Bispecific

AIEli Lilly

NVIDIA and Eli Lilly Launch $1 Billion AI Co‑Innovation Lab to Transform Drug Development

Show More